Articles with public access mandates - Georgina V LongLearn more
Not available anywhere: 49
Review
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ...
The Lancet Oncology 19 (5), 672-681, 2018
Mandates: National Health and Medical Research Council, Australia
Review
Immune checkpoint inhibitors in melanoma
MS Carlino, J Larkin, GV Long
The Lancet 398 (10304), 1002-1014, 2021
Mandates: National Health and Medical Research Council, Australia, National Institute …
Review
PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L 1 clinical trials
J Madore, RE Vilain, AM Menzies, H Kakavand, JS Wilmott, J Hyman, ...
Pigment cell & melanoma research 28 (3), 245-253, 2015
Mandates: National Health and Medical Research Council, Australia
Review
Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma
TN Gide, JS Wilmott, RA Scolyer, GV Long
Clinical Cancer Research 24 (6), 1260-1270, 2018
Mandates: National Health and Medical Research Council, Australia
Review
CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti …
J Edwards, JS Wilmott, J Madore, TN Gide, C Quek, A Tasker, A Ferguson, ...
Clinical Cancer Research 24 (13), 3036-3045, 2018
Mandates: National Health and Medical Research Council, Australia
Review
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
AM Menzies, RN Amaria, EA Rozeman, AC Huang, MT Tetzlaff, ...
Nature medicine 27 (2), 301-309, 2021
Mandates: US National Institutes of Health, National Health and Medical Research …
Review
Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy
SY Lim, JH Lee, TN Gide, AM Menzies, A Guminski, MS Carlino, EJ Breen, ...
Clinical Cancer Research 25 (5), 1557-1563, 2019
Mandates: National Health and Medical Research Council, Australia
Review
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio, V Atkinson, H Schmidt, ...
Nature medicine 25 (6), 941-946, 2019
Mandates: US National Institutes of Health
Review
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
GV Long, RPM Saw, S Lo, OE Nieweg, KF Shannon, M Gonzalez, ...
The Lancet Oncology 20 (7), 961-971, 2019
Mandates: National Health and Medical Research Council, Australia
Review
MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy
J Reinhardt, J Landsberg, JL Schmid-Burgk, BB Ramis, T Bald, N Glodde, ...
Cancer research 77 (17), 4697-4709, 2017
Mandates: National Health and Medical Research Council, Australia, German Research …
Review
Thyroid immune-related adverse events following immune checkpoint inhibitor treatment
CA Muir, RJ Clifton-Bligh, GV Long, RA Scolyer, SN Lo, MS Carlino, ...
The Journal of Clinical Endocrinology & Metabolism 106 (9), e3704-e3713, 2021
Mandates: National Health and Medical Research Council, Australia
Review
PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma
J Madore, D Strbenac, R Vilain, AM Menzies, JYH Yang, JF Thompson, ...
Clinical Cancer Research 22 (15), 3915-3923, 2016
Mandates: National Health and Medical Research Council, Australia
Review
MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer
A Cipponi, DL Goode, J Bedo, MJ McCabe, M Pajic, DR Croucher, ...
Science 368 (6495), 1127-1131, 2020
Mandates: National Health and Medical Research Council, Australia
Review
Intrapatient homogeneity of BRAFV600E expression in melanoma
AM Menzies, T Lum, JS Wilmott, J Hyman, RF Kefford, JF Thompson, ...
The American journal of surgical pathology 38 (3), 377-382, 2014
Mandates: National Health and Medical Research Council, Australia
Review
Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma
A Lepletier, J Madore, JS O'Donnell, RL Johnston, XY Li, E McDonald, ...
Clinical cancer research 26 (14), 3671-3681, 2020
Mandates: National Health and Medical Research Council, Australia
Review
Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors
JH Lee, AM Menzies, MS Carlino, AC McEvoy, S Sandhu, AM Weppler, ...
Clinical Cancer Research 26 (15), 4064-4071, 2020
Mandates: National Health and Medical Research Council, Australia
Review
Clinical models to define response and survival with anti–PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma
I Pires da Silva, T Ahmed, JL McQuade, CA Nebhan, JJ Park, JM Versluis, ...
Journal of Clinical Oncology 40 (10), 1068-1080, 2022
Mandates: National Health and Medical Research Council, Australia, National Institute …
Review
Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
GV Long, JS Wilmott, LE Haydu, V Tembe, R Sharma, H Rizos, ...
Pigment cell & melanoma research 26 (4), 499-508, 2013
Mandates: National Health and Medical Research Council, Australia
Review
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
X Zhang, JZ Tang, IA Vergara, Y Zhang, P Szeto, L Yang, C Mintoff, ...
Molecular Cancer Research 17 (7), 1435-1449, 2019
Mandates: National Health and Medical Research Council, Australia
Review
Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma patients: implications for clinical trials
J Edwards, A Tasker, I Pires da Silva, C Quek, M Batten, A Ferguson, ...
Clinical Cancer Research 25 (11), 3247-3258, 2019
Mandates: National Health and Medical Research Council, Australia
Publication and funding information is determined automatically by a computer program